ARTHEx Biotech Raises $87M Series B Funding

ARTHEx Biotech, a spin-off biotech company focused on developing novel oligonucleotide therapies, has secured $87,000,000 in funding from investors. The Valencia, Spain-based firm specializes in modulating microRNA to treat diseases with significant unmet medical needs. The company has developed a proprietary platform enabling the rapid and flexible development of investigational miR-modulating oligonucleotides. These are designed to enter relevant tissues in pharmacological quantities, targeting diseases where microRNAs play a crucial role. ARTHEx Biotech's lead investigational product, ATX-01, is an antimiR in development for Myotonic Dystrophy Type 1 (DM1). DM1 is an orphan disease affecting over 900,000 people worldwide with no cure or approved treatment available to date. ATX-01 is a first-in-class, disease-modifying therapy that addresses the root cause of DM1 by targeting micro-RNA-23b, a key factor in the disease's pathogenesis, through a dual and unique mechanism of action. This significant capital infusion underscores investor confidence in ARTHEx Biotech's innovative platform and its potential to address critical therapeutic gaps. The company plans to use the funds to advance its research and development pipeline, particularly the continued clinical development of ATX-01, and to expand its proprietary oligonucleotide technology. This investment is crucial for propelling the company's mission to bring groundbreaking treatments to patients suffering from devastating conditions. Looking ahead, ARTHEx Biotech aims to leverage this investment to accelerate its efforts in bringing ATX-01 closer to market and to further explore additional applications of its microRNA-modulating platform for other diseases with high unmet medical needs, reinforcing its commitment to innovation in biotech.